BRCA1 and MAD2 are Co-expressed and are Prognostic Indicators in Tubo-ovarian High-grade Serous Carcinoma

Tara Byrne, Laura Nelson, James Beirne, Daniel Sharpe, Jennifer E. Quinn, W. Glenn McCluggage, Tracy Robson, Fiona Furlong*

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Citations (Scopus)
177 Downloads (Pure)

Abstract

Objectives: The aim of this study was to investigate the relationship between BRCA1 and mitotic arrest deficiency protein 2 (MAD2) protein expression, as determined by immunohistochemistry, and clinical outcomes in epithelial ovarian carcinoma (EOC). Methods: A tissue microarray consisting of 94 formalin-fixed paraffin-embedded EOC with fully matched clinicopathological data were immunohistochemically stained with anti-BRCA1 and anti-MAD2 antibodies. The cores were scored in a semiquantitative manner evaluating nuclear staining intensity and extent. Coexpression of BRCA1 and MAD2 was evaluated, and patient survival analyses were undertaken. Results: Coexpression of BRCA1 and MAD2 was assessed in 94 EOC samples, and survival analysis was performed on 65 high-grade serous carcinomas (HGSCs). There was a significant positive correlation between BRCA1 and MAD2 expression in this patient cohort (P < 0.0001). Both low BRCA1 and low MAD2 are independently associated with overall survival because of HGSC. Low coexpression of BRCA1 and MAD2 was also significantly associated with overall survival and was driven by BRCA1 expression. Conclusion: BRCA1 and MAD2 expressions are strongly correlated in EOC, but BRCA1 expression remains the stronger prognostic factor in HGSC.

Original languageEnglish
Pages (from-to)472-478
JournalInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Volume28
Issue number3
DOIs
Publication statusPublished - 01 Mar 2018

Fingerprint

Protein Deficiency
Carcinoma
Survival Analysis
Survival
Paraffin
Formaldehyde
Immunohistochemistry
Staining and Labeling
Antibodies

Keywords

  • BRCA1
  • Immunohistochemistry
  • MAD2
  • Prognosis
  • Serous ovarian carcinomas

Cite this

Byrne, Tara ; Nelson, Laura ; Beirne, James ; Sharpe, Daniel ; Quinn, Jennifer E. ; Glenn McCluggage, W. ; Robson, Tracy ; Furlong, Fiona. / BRCA1 and MAD2 are Co-expressed and are Prognostic Indicators in Tubo-ovarian High-grade Serous Carcinoma. In: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2018 ; Vol. 28, No. 3. pp. 472-478.
@article{15fed6fcc70e4f3b92974b0c62fc81db,
title = "BRCA1 and MAD2 are Co-expressed and are Prognostic Indicators in Tubo-ovarian High-grade Serous Carcinoma",
abstract = "Objectives: The aim of this study was to investigate the relationship between BRCA1 and mitotic arrest deficiency protein 2 (MAD2) protein expression, as determined by immunohistochemistry, and clinical outcomes in epithelial ovarian carcinoma (EOC). Methods: A tissue microarray consisting of 94 formalin-fixed paraffin-embedded EOC with fully matched clinicopathological data were immunohistochemically stained with anti-BRCA1 and anti-MAD2 antibodies. The cores were scored in a semiquantitative manner evaluating nuclear staining intensity and extent. Coexpression of BRCA1 and MAD2 was evaluated, and patient survival analyses were undertaken. Results: Coexpression of BRCA1 and MAD2 was assessed in 94 EOC samples, and survival analysis was performed on 65 high-grade serous carcinomas (HGSCs). There was a significant positive correlation between BRCA1 and MAD2 expression in this patient cohort (P < 0.0001). Both low BRCA1 and low MAD2 are independently associated with overall survival because of HGSC. Low coexpression of BRCA1 and MAD2 was also significantly associated with overall survival and was driven by BRCA1 expression. Conclusion: BRCA1 and MAD2 expressions are strongly correlated in EOC, but BRCA1 expression remains the stronger prognostic factor in HGSC.",
keywords = "BRCA1, Immunohistochemistry, MAD2, Prognosis, Serous ovarian carcinomas",
author = "Tara Byrne and Laura Nelson and James Beirne and Daniel Sharpe and Quinn, {Jennifer E.} and {Glenn McCluggage}, W. and Tracy Robson and Fiona Furlong",
year = "2018",
month = "3",
day = "1",
doi = "10.1097/IGC.0000000000001214",
language = "English",
volume = "28",
pages = "472--478",
journal = "International journal of gynecological cancer : official journal of the International Gynecological Cancer Society",
issn = "1525-1438",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

BRCA1 and MAD2 are Co-expressed and are Prognostic Indicators in Tubo-ovarian High-grade Serous Carcinoma. / Byrne, Tara; Nelson, Laura; Beirne, James; Sharpe, Daniel; Quinn, Jennifer E.; Glenn McCluggage, W.; Robson, Tracy; Furlong, Fiona.

In: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 28, No. 3, 01.03.2018, p. 472-478.

Research output: Contribution to journalArticle

TY - JOUR

T1 - BRCA1 and MAD2 are Co-expressed and are Prognostic Indicators in Tubo-ovarian High-grade Serous Carcinoma

AU - Byrne, Tara

AU - Nelson, Laura

AU - Beirne, James

AU - Sharpe, Daniel

AU - Quinn, Jennifer E.

AU - Glenn McCluggage, W.

AU - Robson, Tracy

AU - Furlong, Fiona

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objectives: The aim of this study was to investigate the relationship between BRCA1 and mitotic arrest deficiency protein 2 (MAD2) protein expression, as determined by immunohistochemistry, and clinical outcomes in epithelial ovarian carcinoma (EOC). Methods: A tissue microarray consisting of 94 formalin-fixed paraffin-embedded EOC with fully matched clinicopathological data were immunohistochemically stained with anti-BRCA1 and anti-MAD2 antibodies. The cores were scored in a semiquantitative manner evaluating nuclear staining intensity and extent. Coexpression of BRCA1 and MAD2 was evaluated, and patient survival analyses were undertaken. Results: Coexpression of BRCA1 and MAD2 was assessed in 94 EOC samples, and survival analysis was performed on 65 high-grade serous carcinomas (HGSCs). There was a significant positive correlation between BRCA1 and MAD2 expression in this patient cohort (P < 0.0001). Both low BRCA1 and low MAD2 are independently associated with overall survival because of HGSC. Low coexpression of BRCA1 and MAD2 was also significantly associated with overall survival and was driven by BRCA1 expression. Conclusion: BRCA1 and MAD2 expressions are strongly correlated in EOC, but BRCA1 expression remains the stronger prognostic factor in HGSC.

AB - Objectives: The aim of this study was to investigate the relationship between BRCA1 and mitotic arrest deficiency protein 2 (MAD2) protein expression, as determined by immunohistochemistry, and clinical outcomes in epithelial ovarian carcinoma (EOC). Methods: A tissue microarray consisting of 94 formalin-fixed paraffin-embedded EOC with fully matched clinicopathological data were immunohistochemically stained with anti-BRCA1 and anti-MAD2 antibodies. The cores were scored in a semiquantitative manner evaluating nuclear staining intensity and extent. Coexpression of BRCA1 and MAD2 was evaluated, and patient survival analyses were undertaken. Results: Coexpression of BRCA1 and MAD2 was assessed in 94 EOC samples, and survival analysis was performed on 65 high-grade serous carcinomas (HGSCs). There was a significant positive correlation between BRCA1 and MAD2 expression in this patient cohort (P < 0.0001). Both low BRCA1 and low MAD2 are independently associated with overall survival because of HGSC. Low coexpression of BRCA1 and MAD2 was also significantly associated with overall survival and was driven by BRCA1 expression. Conclusion: BRCA1 and MAD2 expressions are strongly correlated in EOC, but BRCA1 expression remains the stronger prognostic factor in HGSC.

KW - BRCA1

KW - Immunohistochemistry

KW - MAD2

KW - Prognosis

KW - Serous ovarian carcinomas

U2 - 10.1097/IGC.0000000000001214

DO - 10.1097/IGC.0000000000001214

M3 - Article

VL - 28

SP - 472

EP - 478

JO - International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

JF - International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

SN - 1525-1438

IS - 3

ER -